# ASPIrin in Reducing Events in Dialysis ( ASPIRED )

Study · id `cardio:ct-nct04381143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04381143](<https://clinicaltrials.gov/study/NCT04381143>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04381143

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 9082 participants.

## Technical summary

Registry record NCT04381143. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-30 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 9082 participants (enrolled count; ClinicalTrials.gov record NCT04381143, source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)
- Started: 2020-07-30 (actual) (ClinicalTrials.gov record NCT04381143, source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT04381143, source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04381143, source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04381143, source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04381143-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: ASPIrin in Reducing Events in Dialysis ( ASPIRED )
- Condition: CKD (Chronic Kidney Disease) Stage 5D
- Intervention (Drug): Aspirin 100 mg Oral Tablet
- Intervention (Drug): Matching Placebo
- Lead sponsor: Guangdong Provincial People's Hospital
- Lead sponsor class: OTHER
- Collaborator: The George Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Guangdong Provincial People's Hospital (`cardio:org-guangdong-provincial-people-s-hospital`)
- Registry lists this organization as a collaborator: The George Institute for Global Health (`core:george-institute`)

## Provenance

Content hash: 3dd177f63ad937b63501de7e6f6ff25e56007973b4aa36d8f216cf0b39341911
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
